About this trial
Acute liver failure (ALF) is a rare but life-threatening condition with high mortality. Despite advances in supportive care and liver transplantation, prognosis varies significantly across etiologies, particularly in patients with indeterminate causes.
This study aims to investigate the dynamic changes of clinical and biochemical indicators, identify potential etiologies-especially in indeterminate ALF-and evaluate prognostic risk factors. A dynamic prediction model will be developed to optimize clinical decision-making, including liver transplantation timing.
Both retrospective and prospective cohorts will be included. Multi-omics analyses (including transcriptomics, proteomics, metabolomics, and metagenomic sequencing) will be performed on liver tissue and biological samples to explore disease mechanisms and etiology.
Eligibility criteria
Qualifiers
Patients (or guardians) who provide informed consent
Disqualifiers
Presence of end-stage extrahepatic disease without effective treatment
Pregnant or breastfeeding women
Inability or unwillingness to provide informed consent or comply with study procedures
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
Sponsors and collaborators
Li-Ying Sun
Lead sponsor
Beijing Friendship Hospital
Sponsor institution